287 related articles for article (PubMed ID: 21691879)
1. Is neo-adjuvant chemotherapy a "waiver" of extensive upper abdominal surgery in advanced epithelial ovarian cancer?
Kang S; Jong YH; Hwang JH; Lim MC; Seo SS; Yoo CW; Park SY
Ann Surg Oncol; 2011 Dec; 18(13):3824-7. PubMed ID: 21691879
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.
Hou JY; Kelly MG; Yu H; McAlpine JN; Azodi M; Rutherford TJ; Schwartz PE
Gynecol Oncol; 2007 Apr; 105(1):211-7. PubMed ID: 17239941
[TBL] [Abstract][Full Text] [Related]
3. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
4. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery.
Stoeckle E; Bourdarias L; Guyon F; Croce S; Brouste V; Thomas L; Floquet A
Ann Surg Oncol; 2014 Feb; 21(2):629-36. PubMed ID: 24052318
[TBL] [Abstract][Full Text] [Related]
5. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
6. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.
Lee SJ; Kim BG; Lee JW; Park CS; Lee JH; Bae DS
J Obstet Gynaecol Res; 2006 Feb; 32(1):99-106. PubMed ID: 16445534
[TBL] [Abstract][Full Text] [Related]
7. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
Gao KF; Liu FY; Chen FJ; Feng YL
Ai Zheng; 2007 Apr; 26(4):431-4. PubMed ID: 17430668
[TBL] [Abstract][Full Text] [Related]
9. [Neo-adjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer treatment--a retrospective study].
Tkácová M; Vertaková-Krakovská B; Belohorská B; Miskovská V; Helpianska L; Ondrus D; Ondrusová M; Spánik S; Svec J
Klin Onkol; 2009; 22(6):273-7. PubMed ID: 20099745
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: a single centre experience.
Bilici A; Salepci T; Dane F; Gumus M; Ustaalioglu BB; Seker M; Salman T; Turan C; Unal O; Yaylaci M
Arch Gynecol Obstet; 2010 Oct; 282(4):417-25. PubMed ID: 20035339
[TBL] [Abstract][Full Text] [Related]
11. The predictors of response to neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yildirim Y; Ertas IE; Dogan A; Gultekin OE; Gultekin E
J Surg Oncol; 2012 Feb; 105(2):200-5. PubMed ID: 21815151
[TBL] [Abstract][Full Text] [Related]
12. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer.
Morice P; Dubernard G; Rey A; Atallah D; Pautier P; Pomel C; Lhommé C; Duvillard P; Castaigne D
J Am Coll Surg; 2003 Dec; 197(6):955-63. PubMed ID: 14644284
[TBL] [Abstract][Full Text] [Related]
13. Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer.
Lim MC; Song YJ; Seo SS; Yoo CW; Kang S; Park SY
Onkologie; 2010; 33(6):324-30. PubMed ID: 20523098
[TBL] [Abstract][Full Text] [Related]
14. Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer.
Lim MC; Yoo HJ; Song YJ; Seo SS; Kang S; Kim SH; Yoo CW; Park SY
J Gynecol Oncol; 2017 Jul; 28(4):e48. PubMed ID: 28541636
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Alshaikh G; Hopkins L; Faught W; Fung MF
Ann Surg Oncol; 2006 Dec; 13(12):1711-6. PubMed ID: 17009146
[TBL] [Abstract][Full Text] [Related]
16. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
Solmaz U; Mat E; Dereli ML; Turan V; Peker N; Tosun G; Dogan A; Adiyeke M; Ozdemir A; Gungorduk K; Sanci M; Yildirim Y
J BUON; 2015; 20(3):847-54. PubMed ID: 26214639
[TBL] [Abstract][Full Text] [Related]
17. The optimal debulking after neoadjuvant chemotherapy in ovarian cancer: proposal based on interval look during upfront surgery setting treatment.
Onda T; Yoshikawa H; Yasugi T; Matsumoto K; Taketani Y
Jpn J Clin Oncol; 2010 Jan; 40(1):36-41. PubMed ID: 19820253
[TBL] [Abstract][Full Text] [Related]
18. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.
Dubernard G; Morice P; Rey A; Camatte S; Fourchotte V; Thoury A; Pomel C; Pautier P; Lhommé C; Duvillard P; Castaigne D
Eur J Surg Oncol; 2004 Nov; 30(9):976-81. PubMed ID: 15498644
[TBL] [Abstract][Full Text] [Related]
19. Omental chemotherapy effects as a prognostic factor in ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Williams K; Senterman M; Hopkins L; Faught W; Fung-Kee-Fung M
Ann Surg Oncol; 2007 Sep; 14(9):2649-53. PubMed ID: 17562112
[TBL] [Abstract][Full Text] [Related]
20. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Bian C; Yao K; Li L; Yi T; Zhao X
Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]